ArQule, Inc. (NASDAQ:ARQL)

CAPS Rating: 2 out of 5

A clinical-stage biotechnology company, engaged in the research and development of cancer therapeutics. Its mission is to research, develop and commercialize targeted cancer drugs with reduced toxicities compared to conventional cancer chemotherapeutics.

Recs

0
Player Avatar iceman7403 (58.79) Submitted: 5/7/2007 5:51:45 PM : Outperform Start Price: $9.08 ARQL Score: -28.10

takeover candidate

Featured Broker Partners


Advertisement